On the next 14th of October, at 10 h, the seminar "Evaluating pathways for therapy against RNA toxicity in myotonicdystrophy type 1" will be held at the Facultad de Medicina y Odontología of the Valencia University. It will be given by Mani S. Mahadevan, M.D, FRCP (Canada) Department of Pathology is Director, Laboratory for Clinical Genomics, UVA Health System, Medical Director, Molec. Diagnostics Lab, UVA Health System, Associate Director, Cytogenetics Lab, UVA-Health System. More information: Tel: 96 386 28 94 and e-mail: email@example.com. This event is related to research activities developed by VLT BIOPHARMA, a biotechnology company born in August 2006 as a University of Valencia spin-off.